How to Use the Program

Participating specialty pharmacies must complete a 1-time registration so they may process ENSPRYNG Co-pay Program* payments. To register, call (800) 636-0373.

The provider sends the prescription. Either the provider or patient sends the patient's Member ID number and Rx BIN to the specialty pharmacy.
The specialty pharmacy collects the patient's co-pay.
The specialty pharmacy uses the Rx BIN to process the ENSPRYNG Co-pay Program as secondary insurance and ships ENSPRYNG to the patient.
The ENSPRYNG Co-pay Program reimburses the specialty pharmacy for the patient's out-of-pocket costs for ENSPRYNG.

*Eligible commercially insured patients who are prescribed ENSPRYNG for an FDA-approved use can receive up to $20,000 in assistance per 12-month period.

Indication and Important Safety Information

ENSPRYNG Important Safety Information

Indication

ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Contraindications

ENSPRYNG is contraindicated in patients with a known hypersensitivity to satralizumab or any of the inactive ingredients, an active hepatitis B infection, or active or untreated latent tuberculosis.

Warnings and Precautions

Infections
Delay ENSPRYNG administration in patients with an active infection until the infection is resolved. Vaccination with live or live attenuated vaccines is not recommended during treatment.

Elevated Liver Enzymes
Monitor ALT and AST levels during treatment; interruption of ENSPRYNG may be required.

Decreased Neutrophil Counts
Monitor neutrophils during treatment.

Most Common Adverse Reactions

The most common adverse reactions (≥15% in either trial) were nasopharyngitis (31%), headache (27%), upper respiratory tract infection (19%), rash (17%), arthralgia (17%), extremity pain (15%), gastritis (15%), fatigue (15%), and nausea (15%).

For additional safety information, please see the full Prescribing Information and Medication Guide.